• Wed news: BioNTech buying Biotheus. FDA’s Califf lists hopes for his successor. Amgen loses $12B market cap from hidden spreadsheet tab. TRex Bio raises $84M. London is Europe’s life science capitol. See more on our front page

Biohaven migraine drug partnered with Pfizer lands twin European approvals

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Apr 27, 2022 at 10:52: PM
via The European Commission approved Biohaven Pharmaceuticals migraine drug rimegepant. While the regulatory decision marks another milestone for Biohaven, it's also a win for Pfizer, which holds rights to commercialize the drug outside of the U.S.

article source
 




Top Bottom
Back
Quote